Head-to-head · Cost-Efficiency Index
Maves vs Rylo Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Maves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesRylo Health
Shoppers who want one flat all-in monthly rate that doesn't rise as the dose increases.
Visit Rylo HealthThe verdict
Maves takes it, leading the Cost-Efficiency Index 76 to 75. Maves (operated by parent company Homera Health) is a men's-health/performance-framed telehealth platform offering compounded semaglutide and tirzepatide plus sermorelin. Rylo Health still earns a C — Shoppers who want one flat all-in monthly rate that doesn't rise as the dose increases.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Maves | Rylo Health |
|---|---|---|
| Cost-Efficiency Index | 76/100 | 75/100 |
| Semaglutide / mo | $89/mo (starting dose, compounded) | $149/mo (all doses, promotional rate, compounded) |
| Tirzepatide / mo | Not disclosed | $249/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $1,068 | $1,788 |
| Tirzepatide / yr (modeled) | — | $2,988 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #49 | #52 |
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Rylo Health
75/100Where the value is
- Stated flat pricing regardless of dose — 'No surprise charges, no tiered pricing' — a genuine differentiator versus tiered competitors
- Medication, provider review, and shipping all stated as included in the quoted price with no add-ons found
- Names its physician group (Lone Star Virtual Health PLLC) and dispensing pharmacy (VialsRX, Houston TX) rather than leaving both anonymous
The tradeoffs
- The '$100/$160 First 20 rate' shown prominently on the homepage is limited to the first 20 signups only — most shoppers will pay the higher $149/$249 standard rate, and the promo framing can make the real price look lower than it is
- The advertised 'quarterly $349/$499' option's actual billing mechanics (one-time total vs. recurring monthly-under-commitment) could not be verified — the product pages that would clarify this render via JavaScript and returned no readable pricing text
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.